SYN-AKE (Pro Viper): Research, Dosing, and Where to Buy in 2026
A research-first profile for SYN-AKE (Pro Viper) (SNK, Pro Viper), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
SYN-AKE (Pro Viper) is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers for SYN-AKE (Pro Viper), each linked to its source.
- Also indexed as SNK, Pro Viper.
- 0 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is SYN-AKE (Pro Viper)?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
SYN-AKE (Pro Viper) Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
No transcript-derived dosing mentions in current source set.
Where to Buy SYN-AKE (Pro Viper) in 2026
No tracked vendor recommendations for SYN-AKE (Pro Viper) yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about SYN-AKE (Pro Viper). Each line links to the original source.
- "Venom exposure exerted a reducing effect on mitochondrial membrane potential (37%, P=0.032) and increased cytochrome c release (2.31-fold, P=0.001)." · Jalili C et al, 2026 PubMed
- "Central America is home to one of the most abundant herpetofauna in the Americas, occupying only 7% of the continent's total area." · Chang Estrada J et al, 2024 PubMed
- "Secondary structure of RVVAP is made up of 36.8% α-helix, 33.3% β pleated sheets and 29.9% turns." · Mukherjee A et al, 2014 PubMed
SYN-AKE (Pro Viper) Research Findings in Numbers
Quantitative results quoted verbatim from the indexed peer-reviewed studies and attributed clinical protocols below.
- P<0.001), FASL (1.28 fold PMID 41693412
- P=0.005), BAX (2.34 fold PMID 41693412
- P<0.001), BAK (1.29 fold PMID 41693412
- P=0.004), and BIM (1.4 fold PMID 41693412
- P<0.001) and downregulation of BCL-2 (0.44 fold PMID 41693412
- P<0.001), BCL-XL (0.47 fold PMID 41693412
Research and Studies
8 PubMed-indexed papers reference SYN-AKE (Pro Viper). Top 8 shown.
Legal Status
SYN-AKE (Pro Viper) is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-16.
Frequently Asked Questions
Is SYN-AKE (Pro Viper) FDA-approved?
SYN-AKE (Pro Viper) is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
How much research has been published on SYN-AKE (Pro Viper)?
8 PubMed-indexed paper(s) reference SYN-AKE (Pro Viper) in our current research feed. See the Research and Studies section above for citations.